May 16, 2024

Less than a year af­ter the end of a PD-1 deal with No­var­tis, BeiGene is look­ing at new part­ner­ships that could bring in new as­sets

Eli Lil­ly reached a set­tle­ment with a South Car­oli­na med­ical spa, mark­ing a win in a broad­er le­gal cam­paign against how com­pounders have mar­ket­ed ver­sions

The World Health Or­ga­ni­za­tion pre­qual­i­fied Take­da’s new dengue vac­cine on Wednes­day, a year af­ter the com­pa­ny with­drew its FDA ap­pli­ca­tion for the can­di­date — though

A bill that would ef­fec­tive­ly force dozens of bio­phar­ma com­pa­nies to cut ties with WuXi AppTec and four oth­er Chi­nese biotech sup­pli­ers by 2032 ad­vanced

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)  Elec­tron­ics gi­ant LG on Mon­day launched a

The In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view said it can­not fair­ly judge Lykos Ther­a­peu­tics’ MD­MA-as­sist­ed ther­a­py for post-trau­mat­ic stress dis­or­der be­cause of con­cerns about cer­tain

Plus, news about Brix­ton Bio­sciences, Mer­ck KGaA, Med­in­cell, Cell­Prothera and GSK: Adap­ti­m­mune inks up to $125M debt fi­nanc­ing: The biotech gets $25 mil­lion to start

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)  GoodRx said on Wednes­day that it has

The car­dio­vas­cu­lar ben­e­fits of No­vo Nordisk’s block­buster weight loss drug We­govy are not de­pen­dent on the amount of weight pa­tients lost, ac­cord­ing to a new

Mer­ck KGaA’s rev­enue from its CD­MO arm dropped in the first quar­ter due to cus­tomer de­stock­ing, but it still ex­pects busi­ness to pick up in